Indication II

Therapy: Porosome Reconstitution in animal studies and human lung organoids. Can treat all 2,500 CFTR mutations as well as patients without CFTR expression.

Status: Preclinical, received FDA Orphan Drug Designation, x2 as effective as the leading drug TRIKAFTA. 

Commercial Value: TRIKAFTA generated >$10 billion in revenue in 2025.